Syntax Bio expands its Series A funding to $14.4 million, bringing total funding to over $25 million, with support from Astellas Venture Management and Draper Associates to develop therapies for type 1 diabetes.
Amount Raised
$14.4 Million
Round Type
Series A
ChicagoBiotechnologyHealth CareTherapeuticsInvestors
Description
Syntax Bio has expanded its Series A funding to $14.4 million, bringing total funding to over $25 million. The funds will help advance its Cellgorithm™ platform and develop pancreatic beta cell therapy for type 1 diabetes. The round includes both new and existing investors. CEO John Craighead expressed optimism about accelerating their gene activation technology.
Quick answer
Syntax Bio raised $14.4 Million in a Series A round, dated June 21, 2026. Investors: LongGame, Illinois Department Of Commerce And Economic Opportunity (Dceo), Walder Ventures, Sigma Group, Exit Fund, Illinois Ventures, Mayo Clinic and Allegis Capital. Syntax Bio is based in Chicago, Illinois, United States.
- How much did Syntax Bio raise?
- Syntax Bio raised $14.4 Million in a Series A round on June 21, 2026.
- Who invested in Syntax Bio?
- LongGame, Illinois Department Of Commerce And Economic Opportunity (Dceo), Walder Ventures, Sigma Group, Exit Fund, Illinois Ventures, Mayo Clinic and Allegis Capital are named as investors in this round.
- What does Syntax Bio do?
- Syntax Bio is a synthetic biology company that specializes in next-generation cell therapies.
- Where is Syntax Bio based and how big is it?
- Syntax Bio is based in Chicago, Illinois, United States. Fundz records about 14 employees.
- Who are the decision-makers at Syntax Bio?
- Fundz holds 2 contacts at Syntax Bio, including the Chief Executive Officer. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who to call at Syntax Bio, and when
A new round usually means Syntax Bio is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Syntax Bio raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Syntax Bio, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Syntax Bio. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Syntax Bio raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meansSyntax Bio raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.